Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PARG | Q86W56 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991844 | 0.85 | GRM2 (0.65) | GRM2GRIN1GRIN2BPARG | |
| SCHEMBL10146618 | 0.85 | GRM2 (0.73) | GRM2GRIN1GRIN2B | |
| SCHEMBL14992292 | 0.84 | GRM2 (0.64) | GRM2PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL10146333 | 0.83 | GRM2 (0.70) | GRM2GRIN1GRIN2BPARG | |
| SCHEMBL624936 | 0.82 | GRM2 (0.66) | GRM2PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL14992746 | 0.82 | GRM2 (0.61) | GRM2GRIN1GRIN2BPARG | |
| SCHEMBL14992462 | 0.81 | GRM2 (0.60) | GRM2PARG | |
| SCHEMBL10146644 | 0.80 | GRM2 (0.52) | GRM2GRIN1GRIN2BPIK3CDPIK3CA | |
| SCHEMBL10146324 | 0.79 | GRM2 (0.76) | GRM2GRIN1GRIN2BPARG | |
| SCHEMBL14992761 | 0.79 | GRM2 (0.57) | GRM2GRIN1GRIN2BPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | claimed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | claimed |
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRIA2, GRM1 | GRM2 1/4885GRIN1 13/4885GRIN2B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.